Beam Therapeutics (BEAM) Enterprise Value (2020 - 2026)

Beam Therapeutics (BEAM) has reported Enterprise Value for 8 consecutive years, with -$1.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 0.68% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (up 0.68% YoY), while the FY2025 annual figure was -$1.2 billion, down 46.37% from the prior year.
• Enterprise Value grew to -$1.2 billion in Q1 2026 per BEAM's latest filing, from -$1.2 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$850.7 million in Q4 2024 and bottomed at -$1.2 billion in Q4 2025.
• Historically, Enterprise Value has averaged -$1.1 billion across 5 years, with a median of -$1.1 billion in 2022.
• Annual changes were most pronounced in 2022 — Enterprise Value sank 142.83% — and 2024, when it climbed 28.5%.
• Beam Therapeutics' Enterprise Value stood at -$1.1 billion in 2022, then dropped by 10.36% to -$1.2 billion in 2023, then grew by 28.5% to -$850.7 million in 2024, then sank by 46.37% to -$1.2 billion in 2025, then grew by 2.69% to -$1.2 billion in 2026.
• Business Quant data shows BEAM's Enterprise Value at -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.